Compare BVFL & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | CRBP |
|---|---|---|
| Founded | 1873 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.8M | 190.3M |
| IPO Year | 2023 | 2014 |
| Metric | BVFL | CRBP |
|---|---|---|
| Price | $21.38 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $33.22 |
| AVG Volume (30 Days) | 10.4K | ★ 1.1M |
| Earning Date | 10-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.00 |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $16.37 | $2.81 |
| 52 Week High | $22.70 | $12.88 |
| Indicator | BVFL | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 32.72 |
| Support Level | $20.36 | $2.81 |
| Resistance Level | $21.86 | $8.13 |
| Average True Range (ATR) | 0.48 | 0.45 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 16.78 | 27.45 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. It operates in one segment commercial banking. The company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.